These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26345559)

  • 1. [Clinical courses and risk factors for progression of smoldering multiple myeloma: a nationwide cohort study in Japan].
    Takamatsu Y; Muta T
    Rinsho Ketsueki; 2015 Aug; 56(8):1005-10. PubMed ID: 26345559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.
    González-Calle V; Dávila J; Escalante F; de Coca AG; Aguilera C; López R; Bárez A; Alonso JM; Hernández R; Hernández JM; de la Fuente P; Puig N; Ocio EM; Gutiérrez NC; García-Sanz R; Mateos MV
    Leukemia; 2016 Oct; 30(10):2026-2031. PubMed ID: 27133826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form.
    Rago A; Grammatico S; Za T; Levi A; Mecarocci S; Siniscalchi A; De Rosa L; Felici S; Bongarzoni V; Piccioni AL; La Verde G; Pisani F; Franceschini L; Paviglianiti AL; Caravita T; Petrucci MT; De Stefano V; Cimino G;
    Cancer; 2012 Nov; 118(22):5544-9. PubMed ID: 22786730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.
    Kastritis E; Terpos E; Moulopoulos L; Spyropoulou-Vlachou M; Kanellias N; Eleftherakis-Papaiakovou E; Gkotzamanidou M; Migkou M; Gavriatopoulou M; Roussou M; Tasidou A; Dimopoulos MA
    Leukemia; 2013 Apr; 27(4):947-53. PubMed ID: 23183429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smoldering multiple myeloma.
    Gao M; Yang G; Kong Y; Wu X; Shi J
    Biomed Res Int; 2015; 2015():623254. PubMed ID: 26000300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature.
    Siragusa S; Morice W; Gertz MA; Kyle RA; Greipp PR; Lust JA; Witzig TE; Lacy MQ; Zeldenrust SR; Rajkumar SV; Russell SJ; Hayman SR; Buadi F; Kumar SK; Dingli D; Dispenzieri A
    Ann Hematol; 2011 Jan; 90(1):101-6. PubMed ID: 20645101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.
    Sørrig R; Klausen TW; Salomo M; Vangsted AJ; Østergaard B; Gregersen H; Frølund UC; Andersen NF; Helleberg C; Andersen KT; Pedersen RS; Pedersen P; Abildgaard N; Gimsing P;
    Eur J Haematol; 2016 Sep; 97(3):303-9. PubMed ID: 26710662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
    Sundararajan S; Kumar A; Korde N; Agarwal A
    Curr Hematol Malig Rep; 2016 Apr; 11(2):102-10. PubMed ID: 26894382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smoldering multiple myeloma: natural history and recognition of an evolving type.
    Rosiñol L; Bladé J; Esteve J; Aymerich M; Rozman M; Montoto S; Giné E; Nadal E; Filella X; Queralt R; Carrió A; Montserrat E
    Br J Haematol; 2003 Nov; 123(4):631-6. PubMed ID: 14616966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.
    Dispenzieri A; Kyle RA; Katzmann JA; Therneau TM; Larson D; Benson J; Clark RJ; Melton LJ; Gertz MA; Kumar SK; Fonseca R; Jelinek DF; Rajkumar SV
    Blood; 2008 Jan; 111(2):785-9. PubMed ID: 17942755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smoldering multiple myeloma: when to observe and when to treat?
    Mateos MV; San Miguel JF
    Am Soc Clin Oncol Educ Book; 2015; ():e484-92. PubMed ID: 25993213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-risk smoldering myeloma: Perspective on watchful monitoring.
    Leng S; Lentzsch S
    Semin Oncol; 2016 Dec; 43(6):697-699. PubMed ID: 28061989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies.
    Kazandjian D; Mailankody S; Korde N; Landgren O
    Clin Adv Hematol Oncol; 2014 Sep; 12(9):578-87. PubMed ID: 25654479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma.
    Ravi P; Kumar S; Larsen JT; Gonsalves W; Buadi F; Lacy MQ; Go R; Dispenzieri A; Kapoor P; Lust JA; Dingli D; Lin Y; Russell SJ; Leung N; Gertz MA; Kyle RA; Bergsagel PL; Rajkumar SV
    Blood Cancer J; 2016 Jul; 6(7):e454. PubMed ID: 27471870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study.
    Kyle RA; Larson DR; Therneau TM; Dispenzieri A; Melton LJ; Benson JT; Kumar S; Rajkumar SV
    Lancet Haematol; 2014 Oct; 1(1):e28-e36. PubMed ID: 25530988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study.
    Tessier C; Allard T; Boudreault JS; Kaedbey R; Éthier V; Fortin F; Pavic M
    Curr Oncol; 2021 May; 28(3):2029-2039. PubMed ID: 34073289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of smoldering multiple myeloma based on nationwide screening.
    Thorsteinsdóttir S; Gíslason GK; Aspelund T; Rögnvaldsson S; Óskarsson JÞ; Sigurðardóttir GÁ; Þórðardóttir ÁR; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Eyþórsson E; Jónsson Á; Berlanga O; Hultcrantz M; Durie BGM; Löve TJ; Harding S; Landgren O; Kristinsson SY
    Nat Med; 2023 Feb; 29(2):467-472. PubMed ID: 36747117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the management of asymptomatic myeloma.
    Mateos MV
    Curr Opin Oncol; 2014 Nov; 26(6):670-6. PubMed ID: 25210868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
    Lakshman A; Rajkumar SV; Buadi FK; Binder M; Gertz MA; Lacy MQ; Dispenzieri A; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
    Blood Cancer J; 2018 Jun; 8(6):59. PubMed ID: 29895887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.